Chair
Kari Nejak-Bowen, PhD
University of Pittsburgh
Session Description: In this session, we will approach the problem of non-alcoholic fatty liver disease (NAFLD) through improved understanding of the cellular and molecular mechanisms involved in disease progression. Recent advances in gut-liver axis, microbiome, and inflammation in the pathogenesis of NAFLD will be also discussed. Finally, we will explore novel signaling pathways that can be targeted for treatment of NAFLD.
| Chair - Welcome and Introductions | ||
| 2:00 PM - 2:30 PM | Cholesterol and Bile Acid Metabolism in Fatty Liver Disease Tiangang Li, PhD • University of Kansas Medical Center |
 |
| 2:30 PM - 3:00 PM | Bile Acid Receptors and NAFLD Huiping Zhou, PhD • Virginia Commonwealth University |
 |
| 3:00 PM - 3:30 PM | Gut Permeability in NASH: Role of Mucosal Immune Cells, Microbiota and Bile Acids Reben Raeman, MS, PhD • University of Pittsburgh |
 |
| 3:30 PM - 4:00 PM | Novel Treatments for NAFLD Naga P. Chalasani, MD • Indiana University |
 |
| 4:00 PM - 4:30 PM | Inhibition of EGFR Receptor Prevents and Reverses Extreme NAFLD George K. Michalopoulos, MD, PhD • University of Pittsburgh |
 |
| 4:30 PM - 5:00 PM | Stress-responsive Gene FKBP5 Mediates Alcohol-induced Liver Injury Through the Hippo Pathway and CXCL1 Signaling Suthat Liangpunsakul, MD • Indiana University |
 |
| Questions and Answers |